Cabazitaxel

Generic Name: Cabazitaxel

Brand Names: Jevtana, Cabazitaxel Accord

Drug Type: Small Molecule

Chemical Formula: C_₄₅H_₅₇NO_₁₄

CAS Number: 183133-96-2

Unique Ingredient Identifier: 51F690397J

Background: Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrie...

Indication: 用于治疗转移性去势抵抗性前列腺癌患者。

Associated Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Associated Therapies: -

Clinical Trials

Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme

Phase 2

Completed

Conditions: Glioblastoma Multiforme (GBM) WHO Grade IV

Interventions: Drug: Cabazitaxel

First Posted Date: 2013-05-31

Last Posted Date: 2017-10-26

Lead Sponsor: University of Ulm

Target Recruit Count: 24

Registration Number: NCT01866449

Locations: 🇩🇪
Lars Bullinger, MD, Ulm, Germany
🇩🇪
Hämatologisch onkologische Praxis, Augsburg, Germany
🇩🇪
Stiftungsklinikum Mittelrhein GmbH, Koblenz, Germany

Cabazitaxel in Relapsed and Metastatic NSCLC

Phase 2

Completed

Conditions: NSCLC

Interventions: Drug: Cabazitaxel

First Posted Date: 2013-05-13

Last Posted Date: 2015-09-28

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 46

Registration Number: NCT01852578

Locations: 🇬🇷
"Ag. Georgios" General Hospital of Chania, Chania, Crete, Greece
🇬🇷
"IASO" General Hospital of Athens Athens, Greece, Athens, Greece
🇬🇷
Air Forces Military Hospital of Athens Athens, Greece, Athens, Greece

and more 2 locations

Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Cabazitaxel with Abiraterone Acetate
Drug: Cabazitaxel

First Posted Date: 2013-05-03

Last Posted Date: 2018-06-04

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 7

Registration Number: NCT01845792

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States

Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)

Phase 2

Conditions: Urothelium Transitional Cell Carcinoma

Interventions: Drug: Cabazitaxel
Drug: Vinflunine

First Posted Date: 2013-04-12

Last Posted Date: 2014-01-28

Lead Sponsor: Associació per a la Recerca Oncologica, Spain

Target Recruit Count: 372

Registration Number: NCT01830231

Locations: 🇳🇱
St. Antoniusziekenhuis, Nieuwegein, Netherlands
🇳🇱
Vumc Amsterdam, Amsterdam, Netherlands
🇳🇱
NKI-AvL, Amsterdam, Netherlands

and more 17 locations

Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

Phase 2

Completed

Conditions: Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma
Distal Esophageal Adenocarcinoma

Interventions: Drug: Cabazitaxel

First Posted Date: 2012-12-28

Last Posted Date: 2018-04-03

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 85

Registration Number: NCT01757171

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

and more 2 locations

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

Phase 2

Withdrawn

Conditions: Castrate-resistant Metastatic Prostate Cancer

Interventions: Drug: Cabazitaxel
Drug: Prednisone
Drug: Granulocyte colony-stimulating factor (G-CSF)

First Posted Date: 2012-12-17

Last Posted Date: 2013-10-16

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT01750866

Cabazitaxel in Platinum Refractory Ovarian Cancer

Phase 2

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Cabazitaxel

First Posted Date: 2012-12-11

Last Posted Date: 2014-12-04

Lead Sponsor: Vejle Hospital

Target Recruit Count: 4

Registration Number: NCT01747239

Locations: 🇩🇰
Herlev Hospital, Herlev, Denmark
🇩🇰
Department of Oncology, Aalborg Hospital, Aalborg, Denmark
🇩🇰
Department of Oncology, Odense University Hospital, Odense, Denmark

and more 1 locations

Phase I/II Cabazitaxel for Recurrent Malignant Glioma

Phase 1

Withdrawn

Conditions: Brain Cancer

Interventions: Drug: Cabazitaxel

First Posted Date: 2012-12-04

Last Posted Date: 2018-01-19

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01740570

Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Cabazitaxel

First Posted Date: 2012-09-26

Last Posted Date: 2017-08-01

Lead Sponsor: Hellenic Cooperative Oncology Group

Target Recruit Count: 84

Registration Number: NCT01693549

Locations: 🇬🇷
2nd Dept of Medical Oncology, Metropolitan Hospital, Athens, Greece
🇬🇷
2nd Dept of Medical Oncology, Agios Savvas Cancer Hospital, Athens, Greece
🇬🇷
Dept of Medical Oncology, Ioannina University Hospital, Ioannina, Greece

and more 14 locations

Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel

Phase 2

Completed

Conditions: Transitional Cell Carcinoma

Interventions: Drug: Cabazitaxel
Other: Best Supportive Care

First Posted Date: 2012-08-20

Last Posted Date: 2018-12-04

Lead Sponsor: Dr Anjali Zarkar

Target Recruit Count: 20

Registration Number: NCT01668459

Locations: 🇬🇧
University Hospitals Birmingham, Birmingham, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy